Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy exchanges : Nyse save search
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
Published: 2024-04-22 (Crawled : 20:00) - globenewswire.com
TOVX | News | $0.411 -1.01% 0.0% 47K
|
Manufacturing
| Email alert
Add to watchlist
vcn-01 cancer pancreatic cell preclinical for meeting potential therapy
ATI Physical Therapy to Announce First Quarter 2024 Financial Results
Published: 2024-04-22 (Crawled : 16:00) - prnewswire.com
ATIP | News | $4.0684 0.95% -0.01% 4.3K
|
Manufacturing
|
| O: 3.23%
H: 2.64%
C: -2.16%
first financial therapy results
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.36 0.91% -0.52% 1.6M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
CRL | News | $232.56 2.55% 0.0% 540K
|
Commercial Services
|
| O: 0.93%
H: 0.36%
C: -0.05%
rare disease collaboration therapeutics therapy
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
TOVX | News | $0.411 -1.01% 0.0% 47K
|
Manufacturing
|
| O: 0.62%
H: 2.02%
C: -1.11%
presentation cell for meeting therapy
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
NVSEF | News | $95.11 5.4% 6.88% 490
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
| Email alert
Add to watchlist
leqvio novartis therapy show
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Published: 2024-04-06 (Crawled : 04:20) - prnewswire.com
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
| Email alert
Add to watchlist
carvykti fda first approved one treatment for therapy
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published: 2024-04-05 (Crawled : 14:00) - biospace.com/
TSVT | $4.67 3.32% 3.21% 410K
|
|
| O: 7.98%
H: 9.06%
C: -9.06%
BMY | $49.14 0.43% 0.12% 6.4M
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: 0.25%
fda for therapy
Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
Published: 2024-04-04 (Crawled : 15:30) - globenewswire.com
SNN | $24.36 2.18% 0.0% 1.4M
|
Health Technology
|
| O: -0.12%
H: 0.1%
C: -0.98%
institute health care system therapy negative
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
BAX | $40.4 2.36% 1.14% 3.3M
|
Health Technology
|
| O: 1.78%
H: 1.13%
C: 0.11%
fda clearance therapy
Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp
Published: 2024-04-01 (Crawled : 18:00) - biospace.com/
LH M | $203.07 0.79% 0.29% 690K
|
Health Services
|
| O: -0.54%
H: 0.23%
C: -0.43%
cell collaboration therapy
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
SNN | $24.36 2.18% 0.0% 1.4M
|
Health Technology
|
| O: -3.19%
H: 0.04%
C: -1.25%
care system therapy living negative
Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: -0.28%
H: 0.27%
C: 0.04%
cancer therapy
Global Continuous Renal Replacement Therapy (CVVH, CVVHDF, CVVHD, SCUF) Industry Research 2024-2033
Published: 2024-03-29 (Crawled : 18:00) - prnewswire.com
CTSO | $0.81 1.0% 2.05% 98K
|
Health Technology
| Email alert
Add to watchlist
MDT | $80.57 1.37% 0.0% 3.8M
|
Health Technology
| Email alert
Add to watchlist
renal research global therapy
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ceo cell therapy
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
Published: 2024-03-22 (Crawled : 23:00) - prnewswire.com
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
| Email alert
Add to watchlist
opsynvi fda first hypertension therapy
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
Published: 2024-03-21 (Crawled : 12:30) - biospace.com/
CRL | News | $232.56 2.55% 0.0% 540K
|
Commercial Services
|
| O: 0.68%
H: 1.71%
C: 1.27%
extension therapy
FDA Approves First Gene Therapy for Rare Pediatric Disease
Published: 2024-03-18 (Crawled : 23:00) - biospace.com/
PRGO | $30.06 -2.4% 0.0% 1.4M
|
Health Technology
|
| O: 0.33%
H: 0.13%
C: -1.51%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 0.2%
H: 0.08%
C: -1.14%
ABT | News | $107.07 -0.2% -0.09% 3.8M
|
Health Technology
|
| O: 1.71%
H: 0.36%
C: -2.52%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
fda rare first disease therapy
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-03-15 (Crawled : 23:00) - biospace.com/
TSVT | $4.67 3.32% 3.21% 410K
|
|
| O: 2.27%
H: 8.4%
C: -0.99%
BMY | $49.14 0.43% 0.12% 6.4M
|
Health Technology
|
| O: -0.32%
H: 1.67%
C: 0.04%
fda therapy
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
Your saved searches
Save your searches and get alerts when important news are released.